Threshold for genetic testing in women with breast cancer needs to be determinedBMJ 2014; 348 doi: https://doi.org/10.1136/bmj.g1863 (Published 06 March 2014) Cite this as: BMJ 2014;348:g1863
- Narendra Nath Basu, oncoplastic breast surgeon1,
- Lester Barr, oncoplastic breast surgeon2,
- D Gareth Evans, professor of medical genetics and cancer epidemiology3,
- Gary L Ross, plastic and reconstructive surgeon and honorary senior lecturer, University of Manchester3
- 1Queen Elizabeth Hospital, Birmingham, UK
- 2University Hospital of South Manchester, Manchester, UK
- 3St Mary’s Hospital, Manchester, UK
US surveillance data describe a 150% increase in contralateral mastectomy in the past decade, so Metcalfe and colleagues’ study of survival in BRCA1 and BRCA2 mutation carriers undergoing contralateral mastectomy after breast cancer is timely.1 2 Since Angelina Jolie’s risk reducing surgery, clinicians often have to counsel patients asking for such procedures.
This study’s findings on survival benefit are similar to our own. …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial